Investor Relations
-
Message from the Chairman and CEO
We are working to meet the expectations of our shareholders and investors by enhancing corporate value.
-
Business Results For the First Six Months of the Fiscal Year Ending March 31, 2020
IR Information
-
- Sysmex Receives Regulatory Approval in China of an in Vitro Diagnostic Reagent to Help Diagnose Breast Cancer Lymph Node Metastasis Using the OSNA™ Method
-Aiming to Introduce a System to Test for Breast Cancer Lymph Node Metastasis into the Chinese Market- -
- Sysmex Launches Gene Testing Kit for Blood Cancer (ipsogen JAK2 DX Reagent)
First Insurance Coverage in Japan for JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms -
- Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - -
- Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
-Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference- -
- Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2020 (PDF：374KB)
